益肾平肝方对原发性高血压患者动态血压及hs-CRP、ICAM-1、SDF-1的影响

Effects of Yishen Pinggan Decoction on Blood Pressure and hs-CRP、ICAM-1、SDF-1 in Patients of Essential Hy Pertension

目的观察益肾平肝方对原发性高血压患者动态血压及血管内皮功能的影响。方法收集阴虚阳亢型原发性高血压患者69例,随机分成中西药结合治疗组(益肾平肝方+科素亚)和西药对照组(科素亚)2组,用药3个月,观察患者在治疗前后的动态血压指标及hs-CRP、ICAM-1、SDF-1的变化。结果西药组、中西药组各项动态血压指标均较治疗前改善(P<0.05);24h SBP、24h DBP、d SBP、d DBP、n SBP治疗后中西药组疗效优于西药组(P<0.05),n DBP治疗后西药组与中西药组未见明显差异(P>0.05),hs-CRP、ICAM-1、SDF-1治疗后中西药组疗效优于西药组(P<0.05)。结论益肾平肝方可以协同西药降低阴虚阳亢型患者的血压,益肾平肝方协同西药能够下调阴虚阳亢型患者的hs-CRP、ICAM-1水平,上调SDF-1水平,改善高血压患者血管内皮损害。

Objective To observe the effects of Yishen Pinggan decoction on high blood pressure and endothelial function with some related indicators. Methods These 69 patients with Yang hyperactivity and Yin deficiency type of essential hypertension were randomly divided into 2 groups, combination of Chinese and western medication group （the Yishen Pinggan decoction and losartan potassium tablets）, western medicine control group （losartan potassium tablets）. Before and after 3-month treatment, the blood pressure and clinical symptoms were tested or measured. The expression of hs-CRP, ICAM-1, SDF-1 levels were measured by commercial ELISA kits. After the treatment, SPSS18. 0 statistical software was used to analysis the results. Results After three months of treatment, all the BP datas were decreased in control and treated group （P〈0.05）, 24hSBP, 24hDBP, dSBP, dDBP, nSBP were decreased more in the treated group （P〈0.05）, no significant difference in nDBP was found between control and treated group （P〉0.05）, which indicates the antihypertensive effect of the treated group is superior to the control group. The endothelial damage relevant indicators were found improved in control and treated group （P〈0.05）, hs-CRP, ICAM-1, SDF-1 were improved more in the treated group （P〈0.05）. Conclusion Yishen Pinggan decoction could decrease blood pressure, improve the Endothelial function which was associated with the decreasing in tile expression of hs-CRP, ICAM-1 and increasing in the expression of SDF-1.